MTX 102

Drug Profile

MTX 102

Alternative Names: C19-A3 GNP; C19-A3 GNP peptide; FP7 EE-ASI; MTX-102

Latest Information Update: 15 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardiff University; Midatech
  • Class Antihypercalcaemics; Immunotherapies; Insulins; Peptide fragments; Peptides; Vaccines
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Type 1 diabetes mellitus

Most Recent Events

  • 02 Sep 2016 Midatech Pharma plans a Bioequivalence trial for Type-1 diabetes mellitus in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top